Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT04899908
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Brain Cancer
- Brain Metastases
- Melanoma
- Lung Cancer
- Breast Cancer
- HER2-positive Breast Cancer
- Colorectal Cancer
- Gastrointestinal Cancer
- SRS
- SRT
- Whole Brain Radiation
- Stereotactic Radiation
- AGuIX
- Nanoparticle
- Cystic
- Brain Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Brigham and Women's Hospital
- Last updated on ClinicalTrials.gov
- September 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Brigham and Women's Hospital · Boston, MA
- Dana Farber Cancer Institute · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.